Is SNSE or GANX more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -83.59% -256.50% Gain Therapeutics N/A -201.44% -136.24%

Which has preferable valuation & earnings, CYPH or SNSE?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is CYPH or SNSE more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -48.33% -42.21% Sensei Biotherapeutics N/A -83.59% -256.50%

Do analysts prefer AIFC or SNSE?

Sensei Biotherapeutics has a consensus price target of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sensei Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has higher valuation and earnings, AIFC or SNSE?

Sensei Biotherapeutics has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.09 -$344.51M N/A N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Does the media favor AIFC or SNSE?

In the previous week, ALT5 Sigma had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 4 mentions for ALT5 Sigma and 2 mentions for Sensei Biotherapeutics. ALT5 Sigma's average media sentiment score of 0.37 beat Sensei Biotherapeutics' score of 0.34 indicating that ALT5 Sigma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SNSE or TLPH more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -83.59% -256.50% Talphera N/A -92.98% -53.22%

Is IBIO or SNSE more profitable?

iBio's return on equity of -53.86% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Sensei Biotherapeutics N/A -83.59% -256.50%

Does the media prefer IBIO or SNSE?

In the previous week, iBio had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 3 mentions for iBio and 2 mentions for Sensei Biotherapeutics. iBio's average media sentiment score of 0.66 beat Sensei Biotherapeutics' score of 0.34 indicating that iBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sensei Biotherapeutics (SNSE) Competitors

$14.14 +0.30 (+2.13%)

Closing price 06/15/2026

Extended Trading

$14.14 0.00 (0.00%)

As of 06/15/2026 07:54 PM Eastern

Compare

SNSE vs. GANX, CYPH, AIFC, TLPH, and IBIO

Should you buy Sensei Biotherapeutics stock or one of its competitors? MarketBeat compares Sensei Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sensei Biotherapeutics include Gain Therapeutics (GANX), Cypherpunk Technologies (CYPH), ALT5 Sigma (AIFC), Talphera (TLPH), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry.

How does Sensei Biotherapeutics compare to Gain Therapeutics?

Sensei Biotherapeutics (NASDAQ:SNSE) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market.

Gain Therapeutics has higher revenue and earnings than Sensei Biotherapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Gain Therapeutics	$50K	1,395.51	-$20.16M	-$0.58	N/A

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 2 mentions for Sensei Biotherapeutics and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.92 beat Sensei Biotherapeutics' score of 0.34 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sensei Biotherapeutics	Neutral
Gain Therapeutics	Very Positive

Sensei Biotherapeutics currently has a consensus price target of $48.00, indicating a potential upside of 239.34%. Gain Therapeutics has a consensus price target of $7.50, indicating a potential upside of 358.44%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sensei Biotherapeutics' return on equity of -83.59% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
Gain Therapeutics	N/A	-201.44%	-136.24%

Summary

Gain Therapeutics beats Sensei Biotherapeutics on 10 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cypherpunk Technologies has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

Cypherpunk Technologies currently has a consensus target price of $0.90, indicating a potential upside of 17.65%. Sensei Biotherapeutics has a consensus target price of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Cypherpunk Technologies' return on equity of -48.33% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Sensei Biotherapeutics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.87 beat Sensei Biotherapeutics' score of 0.34 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
Sensei Biotherapeutics	Neutral

Summary

Cypherpunk Technologies beats Sensei Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

In the previous week, ALT5 Sigma had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 4 mentions for ALT5 Sigma and 2 mentions for Sensei Biotherapeutics. ALT5 Sigma's average media sentiment score of 0.37 beat Sensei Biotherapeutics' score of 0.34 indicating that ALT5 Sigma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ALT5 Sigma has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Sensei Biotherapeutics has a consensus price target of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Sensei Biotherapeutics has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.09	-$344.51M	N/A	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sensei Biotherapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Summary

Sensei Biotherapeutics beats ALT5 Sigma on 7 of the 13 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Talphera?

Sensei Biotherapeutics (NASDAQ:SNSE) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Sensei Biotherapeutics' return on equity of -83.59% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
Talphera	N/A	-92.98%	-53.22%

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 7.0% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Talphera has higher revenue and earnings than Sensei Biotherapeutics. Talphera is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Talphera	$30K	2,499.85	-$14.29M	-$0.31	N/A

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Talphera. MarketBeat recorded 2 mentions for Sensei Biotherapeutics and 1 mentions for Talphera. Talphera's average media sentiment score of 0.94 beat Sensei Biotherapeutics' score of 0.34 indicating that Talphera is being referred to more favorably in the news media.

Company	Overall Sentiment
Sensei Biotherapeutics	Neutral
Talphera	Positive

Sensei Biotherapeutics currently has a consensus target price of $48.00, indicating a potential upside of 239.34%. Talphera has a consensus target price of $3.00, indicating a potential upside of 107.61%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Sensei Biotherapeutics is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Talphera has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Summary

Sensei Biotherapeutics and Talphera tied by winning 7 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to iBio?

iBio (NASDAQ:IBIO) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

iBio presently has a consensus target price of $5.00, indicating a potential upside of 236.70%. Sensei Biotherapeutics has a consensus target price of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

iBio has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

In the previous week, iBio had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 3 mentions for iBio and 2 mentions for Sensei Biotherapeutics. iBio's average media sentiment score of 0.66 beat Sensei Biotherapeutics' score of 0.34 indicating that iBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iBio has higher revenue and earnings than Sensei Biotherapeutics. iBio is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	184.44	-$18.38M	-$0.58	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

7.9% of iBio shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

iBio's return on equity of -53.86% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Summary

iBio beats Sensei Biotherapeutics on 10 of the 14 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNSE vs. The Competition

Export

Metric	Sensei Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.98M	$3.67B	$6.78B	$12.65B
Dividend Yield	N/A	2.19%	2.68%	8.43%
P/E Ratio	-0.10	21.48	27.13	24.40
Price / Sales	N/A	327.86	525.28	91.46
Price / Cash	N/A	143.66	48.59	59.39
Price / Book	0.96	8.55	10.85	6.33
Net Income	-$21.08M	$23.88M	$3.59B	$331.45M
7 Day Performance	N/A	-2.84%	-1.34%	0.18%
1 Month Performance	2.13%	5.93%	2.96%	-0.72%
1 Year Performance	77.92%	52.58%	28.93%	20.53%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNSE Sensei Biotherapeutics	3.0825 of 5 stars	$14.15 +2.1%	$48.00 +239.3%	+75.1%	$18.98M	N/A	N/A	40	News Coverage Gap Up High Trading Volume
GANX Gain Therapeutics	3.6941 of 5 stars	$1.68 -4.5%	$7.50 +346.4%	-9.7%	$75.07M	$50K	N/A	20	Positive News
CYPH Cypherpunk Technologies	2.2114 of 5 stars	$0.73 +4.7%	$0.90 +23.0%	+121.7%	$74.39M	N/A	N/A	40	Positive News Gap Up
AIFC ALT5 Sigma	0.2485 of 5 stars	$0.54 +1.5%	N/A	-92.3%	$74.15M	$24.84M	N/A	170	News Coverage
TLPH Talphera	3.5325 of 5 stars	$1.41 -1.1%	$3.00 +113.5%	+196.5%	$73.70M	$30K	N/A	19	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNSE) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (SNSE) Competitors

SNSE vs. GANX, CYPH, AIFC, TLPH, and IBIO

How does Sensei Biotherapeutics compare to Gain Therapeutics?

Summary

How does Sensei Biotherapeutics compare to Cypherpunk Technologies?

Summary

How does Sensei Biotherapeutics compare to ALT5 Sigma?

Summary

How does Sensei Biotherapeutics compare to Talphera?

Summary

How does Sensei Biotherapeutics compare to iBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (SNSE) Competitors

SNSE vs. GANX, CYPH, AIFC, TLPH, and IBIO

How does Sensei Biotherapeutics compare to Gain Therapeutics?

Which has more volatility and risk, SNSE or GANX?

Which has preferable earnings and valuation, SNSE or GANX?

Does the media prefer SNSE or GANX?

Do analysts rate SNSE or GANX?

Do institutionals & insiders believe in SNSE or GANX?

Is SNSE or GANX more profitable?

Summary

How does Sensei Biotherapeutics compare to Cypherpunk Technologies?

Do insiders & institutionals have more ownership in CYPH or SNSE?

Which has more risk & volatility, CYPH or SNSE?

Which has preferable valuation & earnings, CYPH or SNSE?

Do analysts recommend CYPH or SNSE?

Is CYPH or SNSE more profitable?

Does the media refer more to CYPH or SNSE?

Summary

How does Sensei Biotherapeutics compare to ALT5 Sigma?

Does the media favor AIFC or SNSE?

Which has more risk and volatility, AIFC or SNSE?

Do analysts prefer AIFC or SNSE?

Which has higher valuation and earnings, AIFC or SNSE?

Do institutionals and insiders believe in AIFC or SNSE?

Is AIFC or SNSE more profitable?

Summary

How does Sensei Biotherapeutics compare to Talphera?

Is SNSE or TLPH more profitable?

Do institutionals & insiders believe in SNSE or TLPH?

Which has higher valuation and earnings, SNSE or TLPH?

Does the media refer more to SNSE or TLPH?

Do analysts prefer SNSE or TLPH?

Which has more risk and volatility, SNSE or TLPH?

Summary

How does Sensei Biotherapeutics compare to iBio?

Do analysts rate IBIO or SNSE?

Which has more risk and volatility, IBIO or SNSE?

Does the media prefer IBIO or SNSE?

Which has higher valuation and earnings, IBIO or SNSE?

Do insiders & institutionals hold more shares of IBIO or SNSE?

Is IBIO or SNSE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools